Tag:
Myriad Genetics
Latest Headlines
Latest Headlines
Crescendo raises $56M, enters pact with Myriad
South San Francisco-based Crescendo Bioscience has raised $56 million as a result of completing a $31 million Series C equity financing round and entering an investment agreement with Myriad Genetics
Gene-patent courtroom drama plays out in Washington
The Salt Lake Tribune caught some of the courtroom drama going on at the U.S. Circuit Court of Appeals on Monday, as three judges heard arguments for and against the ability of a private company to
U.S. reverses stance on genes and patents
In a continuing courtroom drama , the federal government filed a brief on Friday saying that genes should not be patentable because they are a part of nature. The New York Times says the position, a
In bombshell, DOJ reverses stance on gene patents
The U.S. Justice Department dropped a bombshell on the biotech industry late Friday, saying that unmodified DNA should not be patentable. Federal attorneys outlined the policy shift in a
Myriad gains from Abbott testing deal
Myriad Genetics announced a deal with Abbott Laboratories in which the Salt Lake City company will perform genetic testing on breast cancer patients in an Abbott study. Abbott wouldn't disclose which
Myriad Genetics appeals gene-patent ruling
Myriad Genetics, a small Salt Lake City company, is finding itself at the center of some pretty large questions over whether its can hold patents on two human genes related to breast and ovarian
Myriad Genetics' shares rise on takeover talk
Shares of Salt Lake City-based Myriad Genetics shot up seven percent Wednesday this week after an analyst with the Royal Bank of Canada Capital Markets said the company would be taken over. Myriad's
Myriad axes 21 jobs, suspends HIV programs in restructuring
With an eye to extending its cash runway past 2013, Salt Lake City-based Myriad Pharmaceuticals announced this morning that it's axing 21 employees and suspending work on its HIV programs while
Javelin and Myriad terminate merger pact
Javelin Pharmaceuticals and Myriad Pharmaceuticals have officially terminated their merger pact, clearing the way for Javelin to accept Hospira's $141 million buyout offer. Hospira's offer was
Javelin jilts Myriad in favor of Hospira's $141M takeover offer
Javelin Pharmaceuticals is dumping Myriad Pharmaceuticals and its $81 million takeover deal in exchange for a much, much better deal from Hospira. Javelin shares skyrocketed 63 percent this morning
